Abstract
BackgroundThe prognosis of patients with recurrent/refractory acute myelogenous leukemia (AML) remains poor and cell-based immunotherapies hold promise to improve outcomes. Natural Killer (NK) cells can elicit an antileukemic response via...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have